IndieBio

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Khepra is a company based in San Francisco, California, that focuses on transforming plastics and agricultural waste into renewable fuels using innovative technology. The company employs a proprietary process that combines ultrasonic technology, frictive heating, cavitation, and acoustic pressure to efficiently break down waste streams. This method utilizes excess renewable electricity generated from solar and wind sources, particularly during times of low energy generation or curtailment. By converting waste into drop-in fuels and renewable chemicals without extraction, Khepra aims to support industries in their transition towards cleaner energy solutions and promote sustainability.

Synthetix is a decentralized protocol based on the Ethereum blockchain that facilitates the issuance of synthetic assets for derivatives trading in decentralized finance (DeFi). Founded in 2017 by Kain Warwick in Sydney, Australia, Synthetix enables users to create and trade synthetic assets that provide exposure to various real-world assets, including currencies, commodities, stocks, and indices. The platform supports a range of financial products such as perpetual futures and options markets, allowing for peer-to-contract trading with infinite liquidity. Synthetix operates through a distributed collateral pool, ensuring users can access synthetic versions of both fiat and cryptocurrencies while maintaining an overview of the entire network.

Khepra is a company based in San Francisco, California, that focuses on transforming plastics and agricultural waste into renewable fuels using innovative technology. The company employs a proprietary process that combines ultrasonic technology, frictive heating, cavitation, and acoustic pressure to efficiently break down waste streams. This method utilizes excess renewable electricity generated from solar and wind sources, particularly during times of low energy generation or curtailment. By converting waste into drop-in fuels and renewable chemicals without extraction, Khepra aims to support industries in their transition towards cleaner energy solutions and promote sustainability.

Khepra is a company based in San Francisco, California, that focuses on transforming plastics and agricultural waste into renewable fuels using innovative technology. The company employs a proprietary process that combines ultrasonic technology, frictive heating, cavitation, and acoustic pressure to efficiently break down waste streams. This method utilizes excess renewable electricity generated from solar and wind sources, particularly during times of low energy generation or curtailment. By converting waste into drop-in fuels and renewable chemicals without extraction, Khepra aims to support industries in their transition towards cleaner energy solutions and promote sustainability.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

Primitives is a public benefit company based in San Francisco, California, specializing in the engineering of advanced biomaterials aimed at mitigating food waste and plastic pollution. The company focuses on manufacturing biodegradable plastics that are designed to help users reduce their environmental impact. Primitives develops environmentally sustainable materials that can be adapted for various applications, producing bioplastic products with innovative properties such as advanced sensing, display capabilities, and enhanced biodegradation. Through its efforts, Primitives seeks to provide effective solutions for businesses looking to address the challenges of plastic pollution.

Primitives is a public benefit company based in San Francisco, California, specializing in the engineering of advanced biomaterials aimed at mitigating food waste and plastic pollution. The company focuses on manufacturing biodegradable plastics that are designed to help users reduce their environmental impact. Primitives develops environmentally sustainable materials that can be adapted for various applications, producing bioplastic products with innovative properties such as advanced sensing, display capabilities, and enhanced biodegradation. Through its efforts, Primitives seeks to provide effective solutions for businesses looking to address the challenges of plastic pollution.

The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Leveraging advanced fermentation to produce functional and nutritional proteins from microorganisms, the Company is reimagining the factory farm model that underpins industrial animal agriculture with a more sustainable, kinder, and healthier alternative. Clara Foods is on a mission to decouple the world's most powerful proteins from the animals that make them.

CASPR Biotech, founded in 2018 and located in San Francisco, California, specializes in the development of a CRISPR-based platform for diagnosing antimicrobial resistances (AMR) and infectious diseases. The company creates portable diagnostic kits that enable the detection of specific DNA and RNA sequences, as well as signature amino acid sequences associated with infectious diseases and genetic mutations. These kits aim to provide healthcare professionals with a simple, rapid, and cost-effective solution for molecular detection, enhancing the accuracy and efficiency of clinical diagnostics.

Guided Clarity, Inc. is a biotechnology company based in San Francisco, California, established in 2018. The company specializes in the development and manufacturing of bioactive peptides aimed at promoting mitochondrial health, particularly for the aging population. Its product line includes medical foods that isolate specific bioactive proteins known for their potential to renew mitochondrial function. Guided Clarity is focused on addressing the health needs associated with aging through innovative nutritional solutions.

MezoMax, Inc. is a biotechnology company based in San Francisco, California, founded in 2017. It specializes in developing oral therapies for nonhealing fractures and bone-related diseases, focusing on enhancing fracture healing and treating osteoporosis, particularly in elderly patients. The company’s innovative product features a novel calcium gluconate stereoisomer that regulates calcium and mineral metabolism, facilitating faster osteogenesis. By stimulating bone-forming cells, MezoMax's small molecule drug offers a safer and more effective approach to bone repair, enabling healthcare professionals to improve patient outcomes in the management of fractures and rare bone diseases.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Proteorex Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for diseases with significant unmet medical needs. Founded in 2014 and headquartered in Toronto, Canada, the company specializes in the creation of small molecule drugs targeting challenging and previously undruggable biological pathways. Utilizing a proprietary platform that integrates innovative synthesis design, computational modeling, and patient-derived cell-based screening, Proteorex aims to expedite the drug discovery process while reducing costs. The company's research primarily emphasizes oncology, leveraging protein-protein interactions to identify and develop new therapeutic candidates. Additionally, Proteorex operates an office in San Francisco, enhancing its reach and collaboration potential within the biotechnology landscape.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

The EVERY Company is the market leader in engineering, manufacturing and formulating animal-free, animal proteins as ingredients for the global food and beverage industry. Leveraging advanced fermentation to produce functional and nutritional proteins from microorganisms, the Company is reimagining the factory farm model that underpins industrial animal agriculture with a more sustainable, kinder, and healthier alternative. Clara Foods is on a mission to decouple the world's most powerful proteins from the animals that make them.

BioLoom is a San Francisco-based company that specializes in the production of bioengineered textiles designed to replace traditional cotton. The company focuses on creating next-generation performance bio-fabrics that are fully customizable, catering specifically to the needs of the fashion and industrial textile industries. By eliminating the dependence on cotton harvesting, BioLoom aims to provide a sustainable alternative that meets contemporary demands for both functionality and environmental responsibility.